MAPT and Alzheimer disease: It is important to note that the acute Aβ1–42 intracerebroventricular injection model captures early amyloid-driven neurotoxicity but does not recapitulate the progressive tau pathology or chronic neuroinflammation characteristic of the full AD spectrum (Yokoyama et al., 2022).